TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19028707

Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) of ketamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (Control group)
Number of subjects: 50
Study: 17265030

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (250 mg every 6 h for 3 days, then 1 mg/kg prednisolone orally for 14 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (50 ml normal saline every 6 h for 3 days, then placebo for 14 days)
Number of subjects: 31
Study: 14751428

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 60
Study: 16563423

Group type: EXPERIMENTAL
Intervention: Memorability-based training
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Source-monitoring training
Number of subjects: 142

Group type: COMPARATOR
Intervention: No training
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Memorability-based training (older children)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Source-monitoring training (older children)
Number of subjects: 142

Group type: COMPARATOR
Intervention: No training (older children)
Number of subjects: 142
Study: 10551636

Group type: EXPERIMENTAL
Intervention: SDZ-RAD (RAD) 0.75 mg/day, 2.5 mg/day, or 7.5 mg/day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8565028

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 17
Study: 1743250

Group type: EXPERIMENTAL
Intervention: Cefadroxil 5 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefadroxil 15 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefadroxil 30 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefadroxil 5 mg.kg‐1 with Cephalexin 45 mg.kg‐1
Number of subjects: 0
Study: 6790688

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent oral feeding
Number of subjects: 11
Study: 29654364

Group type: EXPERIMENTAL
Intervention: Semantic induction task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceptual induction task
Number of subjects: 0
Study: 29309486

Group type: EXPERIMENTAL
Intervention: 0.12 mg ranibizumab
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.20 mg ranibizumab
Number of subjects: 19
Study: 25791743

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural strategies with exercise
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural strategies without exercise
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 75
Study: 24992844

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% povidone iodine (PI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozone (OZ)
Number of subjects: 60
Study: 21762355

Group type: EXPERIMENTAL
Intervention: Inclusion cysts (single/multiple anechoic ≤10‐mm ovarian cysts)
Number of subjects: 48230

Group type: COMPARATOR
Intervention: Normal ovaries
Number of subjects: 48230
Study: 20976384

Group type: EXPERIMENTAL
Intervention: Bovine enamel
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bovine root dentin
Number of subjects: 14
Study: 17344493

Group type: EXPERIMENTAL
Intervention: Reduced-glycemic-load (RGL) diet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-fat, portion-controlled diet (Control)
Number of subjects: 86
Study: 16261949

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 683

Group type: COMPARATOR
Intervention: Standard cohort (control)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Ginkgo cohort
Number of subjects: 683
Study: 11906804

Group type: EXPERIMENTAL
Intervention: Ketoconazole (600-900 mg daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 39
Study: 10460963

Group type: EXPERIMENTAL
Intervention: Dyract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tytin
Number of subjects: 60
Study: 7602349

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel at 200 mg/m2
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel at 135 mg/m2
Number of subjects: 59

Group type: COMPARATOR
Intervention: 1-hour infusion of paclitaxel (both 1-day and 3-day schedules)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1-hour infusion of paclitaxel (both doses)
Number of subjects: 59
Study: 2367614

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30848096

Group type: EXPERIMENTAL
Intervention: 31 g of milk protein supplementation for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Iso-caloric placebo supplementation for 12 weeks
Number of subjects: 116
Study: 28719996

Group type: EXPERIMENTAL
Intervention: Robot-assisted mobilization (30 minutes using Gloreha device)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Robot-assisted mobilization
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (30 minutes additional PT and OT for 3 weeks)
Number of subjects: 32
Study: 26826565

Group type: EXPERIMENTAL
Intervention: Target Temperature Management (TTM) at 33 °C
Number of subjects: 169

Group type: COMPARATOR
Intervention: Target Temperature Management (TTM) at 36 °C
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Baseline MBL levels
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Baseline MAp44 levels
Number of subjects: 169
Study: 24628042

Group type: EXPERIMENTAL
Intervention: Intensive treatment with modified glucose‐insulin‐potassium solution targeting glucose levels of 4.4‐8.3 mmol/l
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional treatment targeting glucose levels of < 13.8 mmol/l
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study: 22128076

Group type: EXPERIMENTAL
Intervention: Daily oral cyclophosphamide (DO)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Pulse cyclophosphamide
Number of subjects: 148
Study: 20388444

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) daily with radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard mouth care only (Control)
Number of subjects: 60
Study: 17452695

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg (12+12) via Aerolizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Salbutamol 600 microg (200+200+200) via meter-dose inhaler
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of Formoterol vs Salbutamol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 60
Study: 15149786

Group type: EXPERIMENTAL
Intervention: Vaccine strain S. typhi Ty21a (pDB1) expressing subunits A and B of recombinant Helicobacter pylori urease (n = 9)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo strain S. typhi Ty21a (n = 4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vaccine strain S. typhi Ty21a (pDB1) (n = 9)
Number of subjects: 13
Study: 12429052

Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 17
Study: 9667709

Group type: EXPERIMENTAL
Intervention: Skin staples for securing the mesh
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polypropylene sutures for securing the mesh (Control)
Number of subjects: 50
Study: 8599745

Group type: EXPERIMENTAL
Intervention: Creatine (5g four times per day for five days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2800988

Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream
Number of subjects: 0
Study: 405998

Group type: EXPERIMENTAL
Intervention: 10% sodium cromoglycate ointment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo ointment (white soft-paraffin base only)
Number of subjects: 21
Study: 31584682

Group type: EXPERIMENTAL
Intervention: Comprehensive care coordination through the CHECK program (n=3126)
Number of subjects: 6259

Group type: COMPARATOR
Intervention: Usual care (n=3119)
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Comprehensive care coordination through the CHECK program
Number of subjects: 6259

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Comprehensive care coordination through the CHECK program (participants with asthma)
Number of subjects: 6259

Group type: COMPARATOR
Intervention: Usual care (participants with asthma)
Number of subjects: 6259

Group type: EXPERIMENTAL
Intervention: Comprehensive care coordination through the CHECK program (participants with sickle cell disease)
Number of subjects: 6259

Group type: COMPARATOR
Intervention: Usual care (participants with sickle cell disease)
Number of subjects: 6259
Study: 29037063

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (5000 or 50,000 IUs weekly) for depression treatment
Number of subjects: 21
Study: 25495266

Group type: EXPERIMENTAL
Intervention: Exposure to cautionary tales (positive/negative conditions)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (no exposure to cautionary tales)
Number of subjects: 305
Study: 23302976

Group type: EXPERIMENTAL
Intervention: Volitionally delayed reporting of AWR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative education and structured postoperative interviews
Number of subjects: 0
Study: 21107534

Group type: EXPERIMENTAL
Intervention: Coordinated intervention program (MTF group)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group vs Intervention group
Number of subjects: 403
Study: 18553033

Group type: EXPERIMENTAL
Intervention: Tepid sponging plus dipyrone (20 mg/kg) for 15 minutes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dipyrone alone (20 mg/kg)
Number of subjects: 120
Study: 15724045

Group type: EXPERIMENTAL
Intervention: 20 mg elemental zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebos
Number of subjects: 0
Study: 11819193

Group type: EXPERIMENTAL
Intervention: Double caudal injection of bupivacaine (0.5 mL kg(‐1) on each occasion) at the end of surgery with unstented Thiersch‐Duplay repair (group 5)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Double caudal injection of bupivacaine (0.5 mL kg(‐1) on each occasion) at the end of surgery with stented Mathieu type repair (group 6)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single caudal injection of 1 mL kg(‐1) of 0.25% plain bupivacaine at the start of surgery with unstented Thiersh‐Duplay repair (group 3)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single caudal injection of 1 mL kg(‐1) of 0.25% plain bupivacaine at the start of surgery with stented Mathieu type repair (group 4)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Double caudal injection versus single caudal injection
Number of subjects: 160
Study: 10029962

Group type: EXPERIMENTAL
Intervention: Activated Electronic Dental Anesthesia (AEDA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonactive Electronic Dental Anesthesia (NAEDA)
Number of subjects: 30
Study: 7574780

Group type: EXPERIMENTAL
Intervention: ACR‐CH (10 mg/person local injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACR aqueous solution (10 mg/person local injection)
Number of subjects: 0
Study: 2185157

Group type: EXPERIMENTAL
Intervention: Ceftriaxone at six times the MIC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ceftriaxone at 1 mg/l
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ampicillin alone or in combination with chloramphenicol
Number of subjects: 33
Study: 7396793

Group type: EXPERIMENTAL
Intervention: eyes open with lighted +20‐diopter lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eyes open with lighted +20‐diopter lenses plus strobe lighting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eyes open in darkness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eyes closed in darkness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eyes closed in a dimly lighted room
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: eyes open with unlighted +20‐diopter lenses plus strobe lighting
Number of subjects: 20
Study: 30060248

Group type: EXPERIMENTAL
Intervention: Single doses of CKA up to 600 mg in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single doses of CKA in rats
Number of subjects: 0
Study: 26831629

Group type: EXPERIMENTAL
Intervention: Autologous Conditioned Plasma (ACP) injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 25603442

Group type: EXPERIMENTAL
Intervention: Motorized diamond burr polishing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual polishing
Number of subjects: 40
Study: 23081753

Group type: EXPERIMENTAL
Intervention: BOC plus PegIFN/RBV for 44 weeks (BOC/PR48)
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Placebo plus PegIFN/RBV for 44 weeks (PR48)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: BOC plus PegIFN/RBV using response-guided therapy (BOC/RGT)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Management of anemia (EPO without RBV dose reduction)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Management of anemia (RBV dose reduction without EPO)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Management of anemia (EPO with RBV dose reduction)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Management of anemia (neither RBV dose reduction nor EPO)
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Overall patients with anemia
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Serious and life-threatening adverse events (AEs) among BOC-treated patients
Number of subjects: 1097
Study: 20846082

Group type: EXPERIMENTAL
Intervention: Electronic ASQ (asthma screening questionnaire) using a tablet computer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Paper-and-pencil ASQ
Number of subjects: 48
Study: 18992654

Group type: EXPERIMENTAL
Intervention: Oral tolvaptan, a vasopressin antagonist
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Oral tolvaptan
Number of subjects: 4133
Study: 16826475

Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine (SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-dose sulfadoxine-pyrimethamine (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 15253884

Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (3g/day, equivalent to 1g/day of n‐3 PUFA) for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Olive oil (3g/day) as placebo
Number of subjects: 65
Study: 11251496

Group type: EXPERIMENTAL
Intervention: Team midwife care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1000
Study: 9071199

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg tid)
Number of subjects: 90
Study: 8220974

Group type: EXPERIMENTAL
Intervention: Fan beam DXA scans (Hologic QDR-2000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pencil beam DXA scans (Hologic QDR-1000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of fan beam and pencil beam data
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fan beam vs. pencil beam for AREA and BMC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall effect on BMD measurements
Number of subjects: 20
Study: 3098273

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29107036

Group type: EXPERIMENTAL
Intervention: BA+CPT (Behavioral Activation + Cognitive Processing Therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPT (Cognitive Processing Therapy)
Number of subjects: 0
Study: 27087678

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) integrated with a self-administered stretching program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 24886671

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy strategy
Number of subjects: 620
Study: 22697270

Group type: EXPERIMENTAL
Intervention: Optic nerve head morphology evaluation
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Visual field performance evaluation
Number of subjects: 246
Study: 20381576

Group type: EXPERIMENTAL
Intervention: Intraoral digital impressions (Lava C.O.S.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Silicone impressions
Number of subjects: 20
Study: 19378437

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15978154

Group type: EXPERIMENTAL
Intervention: Pars Flaccida (PF) pathway
Number of subjects: 202

Group type: COMPARATOR
Intervention: Perigastric (PG) pathway
Number of subjects: 202
Study: 12708105

Group type: EXPERIMENTAL
Intervention: Order of testing (OT tests first or PT tests first) for volunteers
Number of subjects: 167

Group type: COMPARATOR
Intervention: Patients undergoing a multidisciplinary Spine Team Assessment
Number of subjects: 167
Study: 10807146

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (FS)
Number of subjects: 4422
Study: 8868311

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (0.3 microgram/kg/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle (50 ml isotonic saline)
Number of subjects: 18
Study: 1364939

Group type: EXPERIMENTAL
Intervention: Enteric coated granules
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plain tablets
Number of subjects: 16
Study: 4019267

Group type: EXPERIMENTAL
Intervention: 50 micrograms sodium selenate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 micrograms sodium selenate together with 200 mg ascorbic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg ascorbic acid three times daily during meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma GSH‐Px activity
Number of subjects: 0
Study: 31806214

Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 mg twice daily)
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (150 mg twice daily)
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 2725
Study: 29897562

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Sustained response or stable disease (post-chemoradiation baseline)
Number of subjects: 798
Study: 26516724

Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI (once daily)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo DISKUS DPI (twice daily)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Safety assessments
Number of subjects: 287
Study: 23418668

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (2250 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 39
Study: 21074355

Group type: EXPERIMENTAL
Intervention: High-flexion total knee arthroplasty
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 76
Study: 19189275

Group type: EXPERIMENTAL
Intervention: Classical massage treatment (bi-weekly 30-min sessions for 5 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 86
Study: 17697551

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3 (100 mg weekly intravenous infusion during radiotherapy)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3
Number of subjects: 35
Study: 15133322

Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (esters)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (free)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (esters and free)
Number of subjects: 12
Study: 11239311

Group type: EXPERIMENTAL
Intervention: 3-week intervention exercise regimen designed to increase rapidly available distal strength and balance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control exercise regimen
Number of subjects: 20
Study: 9163859

Group type: EXPERIMENTAL
Intervention: Deflazacort (6 mg deflazacort to 5 mg prednisone ratio)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prednisone (control group)
Number of subjects: 82
Study: 8201735

Group type: EXPERIMENTAL
Intervention: S boulardii (1 g/d for 4 weeks) with standard antibiotics
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo with standard antibiotics
Number of subjects: 124
Study: 3146765

Group type: EXPERIMENTAL
Intervention: Sabeluzole (10 mg b.i.d. for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28926204

Group type: EXPERIMENTAL
Intervention: Four nursing clinical decision support interface prototypes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (HANDS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inexperienced participants (<1 year)
Number of subjects: 60
Study: 28495574

Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty combined with bursectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bursectomy alone
Number of subjects: 56
Study: 25545321

Group type: EXPERIMENTAL
Intervention: Latanoprost (LT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Latanoprost (LT) + Narrow band ultraviolet (NB‐UVB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet (NB‐UVB)
Number of subjects: 22
Study: 23058209

Group type: COMPARATOR
Intervention: CIDR
Number of subjects: 61

Group type: COMPARATOR
Intervention: hCG (3300 IU)
Number of subjects: 61

Group type: COMPARATOR
Intervention: CIDR+hCG
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 61